Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

por Nygaard, Marietta, Andersen, Niels Smedegaard, Moser, Claus Ernst, Olesen, Gitte, Schjødt, Ida Marie, Heilmann, Carsten, Sengeløv, Henrik
Publicado 2018